Exosome-related technologies have been developing rapidly over the past few years, and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine.
In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
In May 2017, ExoCoBio Inc. raised US $11 million in a Series A funding round. ExoCoBio is a venture-backed startup that develops exosome-based cosmeceuticals and biopharmaceuticals for skin and tissue regeneration that is headquartered in South Korea.
Companies Mentioned Include:
Anjarium Biosciences
Avalon GloboCare Corp.
Beckman Coulter
Capricor Therapeutics
Cavadis B.V.
Cell Guidance Systems
Codiak Biosciences
CosmoBio USA
Creative Medical Technologies Holdings
Exiqon
ExoCoBio Inc.
Exerkine Corporation
Exopharm
Exosome Diagnostics
Evox Therapeutics
Exogenus Therapeutics
Exosome Sciences
Exosomics Siena SpA
Exostemtech Co. Ltd.
Exovita Biosciences
Galen Lab Supplies
Guangzhou Selaira Stem Cell Technology Co., Ltd
HansaBioMed Life Sciences
iZon Science
Kimera Labs
Lonza
Miltenyi Biotec
Norgen Biotek
ReNeuron
RoosterBio
Unicyte AG
VivaZome Therapeutics
ZenBio
Source: 2018. 3.23